---
schema_version: "secwatch.filing_event.v1"
accession: "0001096906-24-002002"
form_type: "8-K"
ticker: "AXIM"
cik: "0001514946"
company_name: "AXIM BIOTECHNOLOGIES, INC."
filed_at: "2024-10-15T23:59:59+00:00"
generated_at: "2026-05-30T14:32:13.090739+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Change in control at AXIM Biotechnologies; CEO John Huemoeller dies, Catalina Valencia named President

## Summary
- Kettner Investments acquires control via Series C Preferred Stock transfer from Juniper & Ivy and Medical Marijuana, Inc.
- CEO/President John W. Huemoeller II died Oct 12 due to illness; board appointed Catalina Valencia as President on Oct 9.
- Valencia also appointed Series C Director to fill vacancy from Huemoeller's death; she previously founded Sapphire Biotech.
- Series C stock transferred from Juniper to MJNA to satisfy $515K note, then to Kettner to waive $1.09M notes plus $66K interest.

## SEC filing metadata
- accession: 0001096906-24-002002
- form_type: 8-K
- ticker: AXIM
- cik: 0001514946
- company_name: AXIM BIOTECHNOLOGIES, INC.
- filed_at: 2024-10-15T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1514946/000109690624002002/0001096906-24-002002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1514946/000109690624002002/axim-20241009.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001096906-24-002002
- JSON: https://secwatch.observer/filing/0001096906-24-002002.json
- Plain text: https://secwatch.observer/filing/0001096906-24-002002.txt

## Key facts
- Executive change
  Catalina Valencia was appointed as Series C Director at AXIM BIOTECHNOLOGIES, INC..
  - Action: appointed
  - Role: Series C Director
  source text: effective October 14, 2024, Juniper, the record holder of all 500,000 shares of Series C Preferred Stock issued and outstanding, which shares are exclusively entitled to fill any vacancy of a Series C Director seat, appointed Catalina Valencia to fill the Series C Director vacancy
  evidence_url: https://www.sec.gov/Archives/edgar/data/1514946/000109690624002002/0001096906-24-002002-index.htm
- Executive change
  John W. Huemoeller II departed as President and CEO at AXIM BIOTECHNOLOGIES, INC..
  - Action: unable to serve
  - Role: President and CEO
  source text: Due to the fact that the Company's President and CEO, John W. Huemoeller II, was unable to serve as an officer of the Company as a result of serious illness
  evidence_url: https://www.sec.gov/Archives/edgar/data/1514946/000109690624002002/0001096906-24-002002-index.htm
- Executive change
  John W. Huemoeller II departed as Series C Director at AXIM BIOTECHNOLOGIES, INC..
  - Action: died
  - Role: Series C Director
  source text: On October 12, 2024, President and Series C Director, John W. Huemoeller II died as a result of his illness.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1514946/000109690624002002/0001096906-24-002002-index.htm
- Executive change
  Catalina Valencia was appointed as President at AXIM BIOTECHNOLOGIES, INC..
  - Action: appointed
  - Role: President
  source text: on October 9, 2024, the Company’s board of directors appointed Catalina Valencia as the Company’s new President.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1514946/000109690624002002/0001096906-24-002002-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.